255 related articles for article (PubMed ID: 16419008)
1. [Hemolytic uremic syndrome].
Rota S; Cravedi P; Remuzzi G; Ruggenenti P
G Ital Nefrol; 2005; 22 Suppl 33():S57-64. PubMed ID: 16419008
[TBL] [Abstract][Full Text] [Related]
2. [Hemolytic uremic syndrome].
Mele C; Noris M
G Ital Nefrol; 2007; 24(1):23-33. PubMed ID: 17342690
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
4. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
Ito K; Hattori M; Matsumoto N
Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
[TBL] [Abstract][Full Text] [Related]
5. [Hemolytic uremic syndrome in adults].
Hertig A; Ridel C; Rondeau E
Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of hemolytic uremic syndrome after renal transplantation.
Seitz B; Albano L; Vocila F; Mzoughi S; Aoudia R; Guitard J; Ribes D; Vachet-Copponat H; Mourad G; Bienaimé F; Dahan P; Frémeaux-Bacchi V; Cassuto E
Transplant Proc; 2007 Oct; 39(8):2583-5. PubMed ID: 17954182
[TBL] [Abstract][Full Text] [Related]
7. [Hemolytic-uremic syndrome].
Bláhová K
Vnitr Lek; 2004 Jul; 50(7):519-25. PubMed ID: 15323259
[TBL] [Abstract][Full Text] [Related]
8. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
Ferraris JR; Ramirez JA; Ruiz S; Caletti MG; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
Pediatr Nephrol; 2002 Oct; 17(10):809-14. PubMed ID: 12376808
[TBL] [Abstract][Full Text] [Related]
9. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
Bresin E; Daina E; Noris M; Castelletti F; Stefanov R; Hill P; Goodship TH; Remuzzi G;
Clin J Am Soc Nephrol; 2006 Jan; 1(1):88-99. PubMed ID: 17699195
[TBL] [Abstract][Full Text] [Related]
10. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
[TBL] [Abstract][Full Text] [Related]
12. Treatment of typical (enteropathic) hemolytic uremic syndrome.
Bitzan M; Schaefer F; Reymond D
Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
[TBL] [Abstract][Full Text] [Related]
13. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
[TBL] [Abstract][Full Text] [Related]
14. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
[TBL] [Abstract][Full Text] [Related]
15. Complement in typical hemolytic uremic syndrome.
Orth D; Würzner R
Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
[TBL] [Abstract][Full Text] [Related]
16. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
[TBL] [Abstract][Full Text] [Related]
17. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
[TBL] [Abstract][Full Text] [Related]
18. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.
Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M
Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685
[TBL] [Abstract][Full Text] [Related]
19. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
20. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Hirt-Minkowski P; Dickenmann M; Schifferli JA
Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
